# Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma

> **NCT06918015** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 58 (estimated)

## Conditions studied

- BTK Inhibitors
- Follicular Lymphoma
- Immunochemotherapy

## Interventions

- **DRUG:** ZGCVP

## Key facts

- **NCT ID:** NCT06918015
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2028-05-01
- **Final completion:** 2030-05-01
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06918015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06918015, "Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06918015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*